Physicochemical Properties, Toxicity, and Specific Activity of a Follitropin Alpha Biosimilar


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Comparative analysis of the primary structure of recombinant human follicle-stimulating hormone (r-hFSH) in samples of follitropin alpha biosimilar (FAB) preparation and the reference drug Gonal-F showed they were identical while spectral analysis of their secondary and tertiary structures indicated they were bioequivalent. Analytical results for N-glycans and sialic acids revealed that the main glycan structures were similar and the distributions of the main forms of sialic acids in the compared samples differed insignificantly. Results of in vitro and in vivo biological activity testing confirmed that FAB and Gonal-F were equivalent with respect to WHO standards. Comparative testing of the acute and subacute toxicity did not reveal significant differences between the two drugs and also confirmed they were identical. Thus, the investigation proved that FAB and the reference drug were equivalent with respect to the main physicochemical, pharmacodynamic, and toxicological characteristics.

Sobre autores

I. Vorob’ev

Federal Research Centre for Fundamentals of Biotechnology, Russian Academy of Sciences

Email: mikhail.polzikov@gmail.com
Rússia, 33 – 2 Leninskii Prosp., Moscow, 119071

O. Proskurina

All-Russia Scientific Center for Safety Testing of Biologically Active Substances, Ministry of Public Health of the Russian Federation

Email: mikhail.polzikov@gmail.com
Rússia, 23 Kirov St., Staraya Kupavna, Noginskii District, Moscow Oblast, 142450

Yu. Khodak

Federal Research Centre for Fundamentals of Biotechnology, Russian Academy of Sciences

Email: mikhail.polzikov@gmail.com
Rússia, 33 – 2 Leninskii Prosp., Moscow, 119071

A. Gosudarev

N. F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Russian Ministry of Health

Email: mikhail.polzikov@gmail.com
Rússia, 18 Gamaleya St., Moscow, 123098

A. Semikhin

N. F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Russian Ministry of Health

Email: mikhail.polzikov@gmail.com
Rússia, 18 Gamaleya St., Moscow, 123098

D. Byrikhina

N. F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Russian Ministry of Health

Email: mikhail.polzikov@gmail.com
Rússia, 18 Gamaleya St., Moscow, 123098

M. Krasil’shchikova

Shemyakin—Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

Email: mikhail.polzikov@gmail.com
Rússia, 16/10 Miklukho-Maklaya St., Moscow, 117997

B. Mel’nik

Institute of Protein Research, Russian Academy of Sciences

Email: mikhail.polzikov@gmail.com
Rússia, 4 Institutskaya St., Pushchino, Moscow Oblast, 142290

M. Serebryakova

A. N. Belozersky Institute of Physicochemical Biology, Moscow State University

Email: mikhail.polzikov@gmail.com
Rússia, 1/40 Leninskie Gory, Moscow, 119992

M. Polzikov

IVPharma Co.

Autor responsável pela correspondência
Email: mikhail.polzikov@gmail.com
Rússia, 20/2 Nauchnyi Proezd, Moscow, 117246

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media New York, 2017